ArticleAmerican journal of physiology. Endocrinology and metabolism2018
Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.
Article in American journal of physiology. Endocrinology and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Differential effects of testosterone on circulating neutrophils, monocytes, and platelets in men: Findings from two trials.Andrology · 2020Trial
- Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer.Advances in radiation oncology · 2026Article
- Hormonal target validation based on biochemical shifts in gender-affirming hormone therapy.Hormones (Athens, Greece) · 2026Article
- Erythropoietin drug targets and cancer risk: A two-sample Mendelian randomization study.Medicine · 2026Article
- Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial).Korean circulation journal · 2025Article
- Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow.Nature communications · 2025Article
- Severe neutropenia caused by palliative radiation therapy in a case of metastatic hormone-sensitive prostate cancer.IJU case reports · 2024Article
- Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy.World journal of urology · 2024Article
- Article
- Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia.The Journal of nutrition · 2021Observational
- Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure.Haematologica · 2021Article
- Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation.PLoS biology · 2020Article
- Cancer-Related Fatigue: Causes and Current Treatment Options.Current treatment options in oncology · 2020Review
- Testosterone replacement therapy and cardiovascular risk.Nature reviews. Cardiology · 2019Review
- Androgens and Anemia: Current Trends and Future Prospects.Frontiers in endocrinology · 2019Article
- Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Androgen deprivation therapy (ADT) is a mainstay of treatment for prostate cancer (PCa). As androgens stimulate erythropoiesis, ADT is associated with a reduction in hematocrit, which in turn contributes to fatigue and related morbidity. However, the mechanisms involved in ADT-induced reduction in erythropoiesis remain unclear. We conducted a 6-mo prospective cohort study and enrolled men with PCa about to undergo ADT (ADT-Group) and a control group of men who had previously undergone prostatectomy for localized PCa and were in remission (Non-ADT Group). All participants had normal testosterone levels at baseline. Fasting blood samples were collected at baseline, 12 wk, and 24 wk after initiation of ADT; samples were obtained at the same intervals from enrollment in the Non-ADT group. Blood count, iron studies, erythropoietin, erythroferrone, and hepcidin levels were measured. Seventy participants formed the analytical sample (31 ADT, 39 Non-ADT). ADT was associated with a significant reduction in erythrocyte count (estimated mean difference = -0.2×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.